| B. Notwithstanding paragraph A, the department may | terminate or suspend the participation of a provider in the | MaineCare program in lieu of recoupment pending final | determination regarding an overpayment as long as 30 days' | notice is given pursuant to federal regulation and state | rule. |
|
| | Sec. C-7. 22 MRSA §42, sub-§7, ¶H, as amended by PL 2003, c. 613, §2, | is further amended to read: |
|
| H. In an administrative appeal of an informal review | decision under this subsection, the department bears the | burden of proving a violation of law or rule by a | preponderance of the evidence. If the department proves | that existing and available records of goods or services are | defective, the department may impose a fee penalty or | sanction, including total recoupment. Total recoupment for | defective records is warranted only when the provider has | failed to demonstrate by a preponderance of the evidence | that the disputed goods or services were medically | necessary, MaineCare-covered goods or services and were | actually provided to eligible MaineCare members. |
|
| | Sec. C-8. 22 MRSA §2698-A, sub-§§3, 4 and 6, as reallocated by RR 2003, | c. 1, §17 and affected by §18, are amended to read: |
|
| | 3. Manner of reporting. By July 1st Beginning in 2006, by | July 1st each year, a manufacturer or labeler of prescription | drugs that directly or indirectly distributes prescription drugs | for dispensation to residents of this State shall file a report | with the department in the form and manner provided by the | department. The report must be accompanied by payment of a fee, | as set by the department in rule, to support the work of the | department under this section. |
|
| | 4. Content of annual report by manufacturer or labeler. The | annual report filed under subsection 3 must include the following | information for each calendar year, beginning with calendar year | 2005, as it pertains to marketing activities conducted within | this State in a form that provides the value, nature, purpose and | recipient of the expense: |
|
| A. All expenses associated with advertising, marketing and | direct promotion of prescription drugs through radio, | television, magazines, newspapers, direct mail and telephone | communications as they pertain to residents of this State, | except for expenses associated with advertising purchased | for a regional or national market that includes advertising | within the State; |
|
|